Featured Press Releases

BioClear Toenail Fungus Device Under Review: Effective LED Laser for Healthy Nails & Discoloration Treatment

BioClear Toenail Fungus Device Under Review: Effective LED Laser for Healthy Nails & Discoloration Treatment

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

  • 22 Jul 2024

The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor...

Nested Therapeutics Receives FDA Clearance for IND Application of NST-628, a Groundbreaking Pan-RAF/MEK Molecular Glue

Nested Therapeutics Receives FDA Clearance for IND Application of NST-628, a Groundbreaking Pan-RAF/MEK Molecular Glue

To Advance Pharmacogenomics in Healthcare, Gene by Gene and myDNA Are Partnering with the University of Glasgow

To Advance Pharmacogenomics in Healthcare, Gene by Gene and myDNA Are Partnering with the University of Glasgow's Living Laboratory

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

  • Abbott
  • 01 Sep 2026
Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026
Choose Health Launches Comprehensive At-Home Liver Function Test Featuring 20+ Biomarkers and Clinical Risk Scores

Choose Health Launches Comprehensive At-Home Liver Function Test Featuring 20+ Biomarkers and Clinical Risk Scores

  • Choose Health
  • 28 Aug 2026
Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.